gilteritinib-resistant FLT3 mutants don't bind gilteritinib

Stable Identifier
R-HSA-9702589
Type
Reaction [transition]
Species
Homo sapiens
Compartment
plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
gilteritinib-resistant FLT3 mutants don't bind gilteritinib
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The following FLT3 mutants are resistant to inhibition by gilteritinib:

FLT3 F691L (partial: Mori et al, 2017; Tarver et al, 2020)
FLT3 F691I (partial: Mori et al, 2017)
Literature References
PubMed ID Title Journal Year
28516360 Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

Ueno, Y, Yamada, M, Kaneko, N, Kuromitsu, S, Mori, M, Saito, R, Shimada, I, Mori, K, Tanaka, R

Invest New Drugs 2017
32040554 Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Perl, AE, Mori, K, Hill, JE, Tarver, TC, Bahceci, E, Smith, CC, Rahmat, L

Blood Adv 2020
Participants
Input
Participates
as an event of
Normal reaction
FLT3 binds type I TKI (Homo sapiens)
Functional status

Loss of function of gilteritinib-resistant FLT3 mutants [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Rothfels, K  (2020-11-06)
Reviewed
Kazi, JU  (2020-11-06)
Created
Rothfels, K  (2020-10-01)
Cite Us!